What Retina Specialists Have Learned From TRUCKEE - Takeaways - MDSpire

What Retina Specialists Have Learned From TRUCKEE

Carl J. Danzig, MD, reviews 4.5 years of real-world findings showing sustained anatomic improvements, longer treatment intervals, and a favorable safety profile with faricimab in neovascular AMD.

  • By

  • Carl Danzig, MD

  • July 15, 2026

  • 3 min

Share

  • 1

    The TRUCKEE study evaluated faricimab's efficacy and safety in neovascular age-related macular degeneration over 4.5 years.

  • 2

    Faricimab showed sustained anatomic improvements and longer treatment intervals in both treatment-naïve and previously treated patients.

  • 3

    The study involved over 3,600 eyes and 2,900 patients, with nearly 22,000 injections administered.

  • 4

    Patients switching from aflibercept to faricimab experienced nearly 2-week extension in treatment intervals after 9 injections.

  • 5

    Faricimab demonstrated a low rate of intraocular inflammation and all reported adverse events resolved with vision returning to baseline.

Original Source(s)

What Retina Specialists Have Learned From TRUCKEE

  • by Carl Danzig, MD

  • July 15, 2026

Related Content

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

Longitudinal assessment of intraocular pressure in the 5xFAD mouse model of Alzheimer's disease

Efficacy of intradermal acupuncture for ocular surface diseases secondary to refractory peripheral facial palsy: a randomized controlled trial study protocol